Integer Holdings Class Action Notice: Compensation Deadline February 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy ITGR?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Integer Holdings (NYSE:ITGR) common stock between July 25, 2024, and October 22, 2025, to apply as lead plaintiffs by February 9, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, alleviating financial burdens for participants.
- Lawsuit Background: The lawsuit alleges that Integer overstated its competitive position in the electrophysiology market and failed to disclose deteriorating sales, leading to investor losses when the truth emerged, thereby damaging the company's market reputation.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ITGR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ITGR
Wall Street analysts forecast ITGR stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 85.380
Low
75.00
Averages
86.25
High
95.00
Current: 85.380
Low
75.00
Averages
86.25
High
95.00
About ITGR
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
Irenic Capital Acquires $99.11 Million Stake in Integer Holdings
- New Position Disclosure: On February 17, 2026, Irenic Capital Management LP disclosed a new position by acquiring 1,263,663 shares of Integer Holdings, with an estimated trade value of $99.11 million, highlighting its significant investment in the company.
- Holding Proportion Analysis: This acquisition positions Irenic's stake in Integer Holdings at 13.7% of its total assets under management, reflecting confidence in the company's growth potential despite a 37.9% decline in the stock over the past year.
- Financial Performance Overview: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, and despite pressures from debt conversion costs, management remains optimistic about 2026.
- Market Outlook: Management projects adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating long-term investment potential in the cardiac and vascular sectors.
See More
Irenic Capital Management Acquires Stake in Integer Holdings
- New Position Disclosure: Irenic Capital Management disclosed a new position in Integer Holdings by acquiring 1,263,663 shares in Q4 2026, valued at approximately $99.11 million, making it the fund's largest disclosed equity position, reflecting strong confidence in the company.
- Performance Growth: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion, with a 21% increase in adjusted EPS to $6.40, showcasing the company's robust performance in the medical device sector.
- Future Outlook: Management anticipates adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating a positive outlook for the future.
- Portfolio Allocation: Irenic's stake in Integer Holdings represents 13.7% of its equity assets, which, while not dominant, aligns with its activist strategy targeting operationally solid companies to drive valuation and capital allocation catalysts.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Investigation into Integer Holdings Board for Fiduciary Breach
- Sales Guidance Cut: On October 23, 2025, Integer Holdings Corporation lowered its full-year 2025 sales guidance to between $1.840 billion and $1.854 billion, falling short of prior expectations, indicating significant market challenges and sluggish growth.
- Decline in New Product Sales: During the subsequent earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting that market adoption has been slower than anticipated, which could adversely affect future revenues.
- Severe Market Reaction: This news caused Integer's stock price to plummet by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, directly impacting investor confidence and the company's market capitalization.
- Legal Investigation Initiated: The Law Offices of Howard G. Smith announced an investigation into whether Integer's board breached its fiduciary duties to shareholders, potentially leading to shareholder losses, and is calling on affected shareholders to participate in discussions.
See More
Five9 Securities Fraud Class Action Survives Dismissal Motion
- Lawsuit Survives: The securities fraud class action against Five9 has survived a motion to dismiss in federal court, indicating that plaintiffs allege executives failed to disclose underperformance, potentially leading to financial losses for shareholders.
- Misrepresentation of Performance: Plaintiffs claim that Five9 executives falsely represented the strength of new business bookings during the first half of 2024, forcing the company to cut its annual revenue guidance, which negatively impacts investor confidence.
- Shareholder Actions: Shareholders holding Five9 stock can seek corporate reforms and fund returns, reflecting a strong demand for improved governance and transparency, which may prompt the company to adopt stricter compliance measures.
- Legal Consequences: The progress of this case could negatively affect Five9's stock price, necessitating investor attention on subsequent legal proceedings and their potential impact on the company's operations.
See More
Investigation into Integer Holdings Board's Potential Breach of Fiduciary Duties
- Sales Guidance Cut: On October 23, 2025, Integer Holdings lowered its full-year sales guidance to a range of $1.840 billion to $1.854 billion, falling short of market expectations, indicating significant growth challenges that could undermine investor confidence.
- Declining Product Sales Forecast: During the earnings call, management revealed that sales of three new products, including two electrophysiology devices, are expected to decline in 2026, suggesting slower market adoption than anticipated, which may lead to future revenue declines.
- Slowing Cardiovascular Growth: The anticipated slowdown in sales growth for the Cardio & Vascular segment due to declines in electrophysiology products is expected to persist into 2026, further impacting the company's overall performance.
- Significant Stock Price Drop: Following the announcement, Integer's stock price plummeted by $35.22, or 32.3%, closing at $73.89 on October 23, 2025, resulting in substantial losses for investors.
See More
Irenic Capital Acquires $99.11 Million Stake in Integer Holdings
- New Position Disclosure: On February 17, 2026, Irenic Capital Management LP disclosed a new position by acquiring 1,263,663 shares of Integer Holdings, with an estimated trade value of $99.11 million, highlighting its significant investment in the company.
- Holding Proportion Analysis: This acquisition positions Irenic's stake in Integer Holdings at 13.7% of its total assets under management, reflecting confidence in the company's growth potential despite a 37.9% decline in the stock over the past year.
- Financial Performance Overview: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion in revenue, with a 21% increase in adjusted EPS to $6.40, and despite pressures from debt conversion costs, management remains optimistic about 2026.
- Market Outlook: Management projects adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating long-term investment potential in the cardiac and vascular sectors.
See More
Irenic Capital Management Acquires Stake in Integer Holdings
- New Position Disclosure: Irenic Capital Management disclosed a new position in Integer Holdings by acquiring 1,263,663 shares in Q4 2026, valued at approximately $99.11 million, making it the fund's largest disclosed equity position, reflecting strong confidence in the company.
- Performance Growth: Integer Holdings achieved an 8% sales growth in 2025, reaching $1.85 billion, with a 21% increase in adjusted EPS to $6.40, showcasing the company's robust performance in the medical device sector.
- Future Outlook: Management anticipates adjusted EPS for 2026 to be between $6.29 and $6.78, with plans to achieve organic growth exceeding market rates by 200 basis points in 2027, indicating a positive outlook for the future.
- Portfolio Allocation: Irenic's stake in Integer Holdings represents 13.7% of its equity assets, which, while not dominant, aligns with its activist strategy targeting operationally solid companies to drive valuation and capital allocation catalysts.
See More
